Bristol-Myers Squibb held its BMY Q1 2026 earnings conference call on April 30, 2026, with management highlighting a late-stage pipeline approaching a cluster of pivotal readouts across cardiovascular disease, fibrotic lung disease, neuroscience, and hematology. The key near-term catalysts include milvexian in AFib and secondary stroke prevention, admilparant in IPF, Cobenfy in Alzheimer’s disease psychosis, and the company’s CELMoD protein degradation platform in relapsed or refractory multiple myeloma. Management framed these readouts as central to defining BMS’s growth profile into the next decade.
Key Strategic Signals
CELMoD Platform: The iberdomide new drug application was accepted by the US FDA with Breakthrough Therapy Designation and Priority Review, carrying a PDUFA date of August 17, 2026. Separately, mezigdomide hit a positive interim progression-free survival endpoint in the SUCCESSOR-2 Phase III trial ahead of schedule, with full data to be presented at ASCO. Chief Medical Officer Cristian Massacesi said the company intends to position both iberdomide and mezigdomide as replacements for Revlimid (lenalidomide) and Pomalyst (pomalidomide) in second-line relapsed or refractory multiple myeloma (RRMM), with longer-term ambitions to pair them with T-cell redirecting therapies and cell therapy.
Admilparant: The company's LPA1 inhibitor admilparant is advancing through Phase III trials in idiopathic pulmonary fibrosis (IPF), with a readout guided for the second half of 2026, and progressive pulmonary fibrosis (PPF), with data expected in early 2027. Massacesi cited Phase II results showing greater than 60% improvement versus placebo in lung function decline at the 60 milligram twice-daily dose, a clear dose-response relationship across tested doses, and ongoing Data Monitoring Committee reviews recommending continuation without safety flags. The company is running both Phase III studies with two doses — 60 milligram and 120 milligram — providing two shots at demonstrating efficacy. Management described admilparant as first-in-class for both indications with a tolerability profile meaningfully differentiated from current antifibrotics, where approximately 50% to 60% of patients discontinue therapy within 12 months.
Non-Obstructive HCM: Massacesi announced that BMS is planning a new, more focused Phase III study in non-obstructive hypertrophic cardiomyopathy (HCM) for Camzyos (mavacamten), informed by learnings from the ODYSSEY trial. He said the company now has a clearer understanding of which patient subpopulations and disease subtypes are most likely to benefit from myosin inhibition, and that trial details would be registered on ClinicalTrials.gov. This represents a strategic attempt to recover a previously failed indication through refined patient selection.
Analyst Pressure Points
Milvexian Trial Design and Subgroup Risk: Analysts from Wolfe Research and UBS pressed management on whether the milvexian AFib trial — the Librexia program — could produce a partial or ambiguous result, and whether historically lower stroke event rates in contemporary AFib trials could delay the readout into 2027. Massacesi acknowledged the study is event-driven and that the company remains blinded, but said the predefined event count for both efficacy and safety is accruing as planned and that a year-end readout remains the base case. He declined to specify a bleeding reduction threshold required for commercial success, and analysts noted the non-inferiority margins of 0.84 to 1.3 on efficacy leave meaningful room for interpretation if the efficacy result lands close to the boundary.
Cobenfy ADEPT Program Heterogeneity: Analysts at Jefferies questioned why BMS added mandatory biomarker confirmation of Alzheimer's diagnosis to the ADEPT-4 trial design — requiring plasma or imaging confirmation — when ADEPT-2 was already enrolling without that requirement. Massacesi said the decision was made to reduce patient population heterogeneity and increase confidence that enrolled patients have confirmed Alzheimer's disease, while acknowledging that the biomarker screening requirement increases operational complexity and screening failures. He framed ADEPT-2 and ADEPT-4 as parallel shots on goal, with the company requiring at least two positive studies for a regulatory filing. BMS has since added ADEPT-5 to the program, giving it four trials in Alzheimer's disease psychosis (ADP).
Forward-Looking Catalysts
H2 2026 — Milvexian Phase III Readouts (AFib and SSP): Both the Librexia AFib trial, enrolling 20,500 patients in a head-to-head comparison against apixaban, and the secondary stroke prevention (SSP) trial are on track for year-end readouts. The AFib study is powered to demonstrate non-inferiority on stroke prevention and superiority on bleeding, with the bleeding endpoint split between measured bleeds and clinically relevant non-major bleeds. Chief Commercialization Officer Adam Lenkowsky said payers are not anchored to a specific percentage bleeding reduction threshold but are seeking a clinically meaningful and statistically credible reduction in major bleeds that translates into fewer hospitalizations. BMS would be the only company with a Factor XIa inhibitor approved in both AFib and SSP if successful.